טוען...
Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
INTRODUCTION: The aim of the present study was to assess the long‐term (52‐week) efficacy and safety of ipragliflozin in insulin‐treated Japanese patients with type 1 diabetes mellitus and inadequate glycemic control. MATERIALS AND METHODS: In this 28‐week, open‐label extension of a multicenter, ran...
שמור ב:
| הוצא לאור ב: | J Diabetes Investig |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232286/ https://ncbi.nlm.nih.gov/pubmed/31743569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13181 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|